Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4979 - Neoadjuvant therapy for esophageal adenocarcinoma: A propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapy

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy;  Radiation Oncology

Tumour Site

Oesophageal Cancer

Presenters

Andrew Barbour

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

A.P. Barbour1, S. Brosda2, B. Wijnhoven3, S. van Hootgem3, J.J..B. Lanschot4, S. Barbour5, S. Lagarde3, L. Krause1, D. Pryor6, J. Thomas7, E.T. Walpole8, A. van der Gaast9, M. Smithers7

Author affiliations

  • 1 Diamantina Institute, The University of Queensland, 4102 - Woolloongabba/AU
  • 2 Diamantina Institute, University of Queensland, 4102 - Woolloongabba/AU
  • 3 Department Of Surgery, Erasmus Medical Center, Rotterdam/NL
  • 4 Department Of General Surgery, Erasmus Medical Center, Rotterdam/NL
  • 5 Radiation oncology Centre, Greenslopes Private Hospital, 4120 - Greenslopes/AU
  • 6 Radiation oncology, Princess Alexandra Hospital, 4102 - Woolloongabba/AU
  • 7 Department Of Surgery, Princess Alexandra Hospital, 4102 - Woolloongabba/AU
  • 8 Medical Oncology, Princess Alexandra Hospital, 4102 - Woolloongabba/AU
  • 9 Medical Oncology, Erasmus University Medical Center, 3015 CE - Rotterdam/NL

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4979

Background

Multimodality treatments of patients with esophageal adenocarcinoma (EAC) improve survival, but the optimal treatment strategy remains undetermined. This study aimed to compare response, local recurrence and survival outcomes in patients undergoing neoadjuvant paclitaxel and carboplatin chemoradiotherapy with 41Gy (CROSS) with neoadjuvant cisplatin and 5-fluoruracil (CF)-based chemoradiotherapy with 45Gy (CFRT) or CF chemotherapy followed by oesophagectomy for EAC.

Methods

Patients who underwent CROSS, CFRT or CF followed by surgery for EAC were identified from two single institution prospective databases from Australia and the Netherlands (2000-2018) and included in this study. After pair-wise propensity score matching (caliper 0.2) using pre-treatment variables (age, gender, year of treatment, tumor length and site, and clinical T stage), we compared the impact of the treatments on pathological outcomes, patterns of recurrence and overall survival.

Results

Of the 637 eligible patients, 429 patients were analysed following propensity score matching. This resulted in 143 patients in each group with median follow up 61 months. CROSS and CFRT demonstrated significantly higher pathological complete response rates (p < 0.001), lower ypT stage (p < 0.001) and lower ypN stage (p < 0.001) compared with CF. There were no statistically significant differences in 5-year local recurrence-free survival between the three treatment groups: CROSS 76% (95%CI: 68-85); CFRT 71% (95%CI: 64-81); and CF 66% (95%CI: 65-76). Similarly, there were no significant differences in 5-year overall survival rates between groups: CROSS 52% (95%CI: 44-62); CFRT 40% (95%CI: 32-49); and 46% (95%CI: 38-55)(p = 0.18, log rank). Median overall survival for CROSS was 69 months (95%CI: 47-139), for CFRT 32 months (95%CI: 26-52), and for CF 47 months (95%CI: 33-66) (p = 0.33, log rank).

Conclusions

In this study, there were higher pathological response rates and lower pathological stage associated with CROSS and CFRT. However, overall survival and local recurrence was similar for CROSS, CF and CFRT.

Clinical trial identification

Legal entity responsible for the study

The University of Queensland.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.